Browse by category

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

The FDA has cleared Alveus Therapeutics’ Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase 1b clinical study. The first patient was dosed last week. ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tol

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may significantly improve post-surgical outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and obesity, according to a study led by Cleveland Clinic researchers. At one-year follow-up, patients taking GLP-1RAs showed a 36% reduction in the need for revision sinus surgery. Additionally, at five years post-surgery, patients experienced a 40% reduction in revision surgery rates and a 28% decrease in f

Postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, according to a study led by Mayo Clinic researchers. Concurrent use of hormone therapy and tirzepatide was also associated with improved cardiometabolic outcomes, suggesting that hormone therapy might enhance the therapeutic effects of tirzepatide in this population. "This study provides important insights for developing more effective and personalized strategies for manag

The long-term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric adenocarcinoma, according to a study of Nordic health data. "The results of this study do not support the hypothesis that long-term proton pump inhibitor use is associated with an increased risk of gastric adenocarcinoma,” the researchers noted. “This finding should offer relief for patients needing lon

Metabolic bariatric surgery (MBS) may improve psoriasis severity, quality of life and treatment requirements - weight loss magnitude, type of MBS and patient characteristics might affect clinical response of psoriasis, however, the current evidence is uncertain, according to researchers from Hull University Teaching Hospitals NHS Trust, in the UK. (Credit: Bobjgalindo) The researchers noted that although MBS has been associated with improved clinical outcomes of psoriasis, ye